Global Malignant Mesothelioma Market Growth (Status and Outlook) 2024-2030

Global Malignant Mesothelioma Market Growth (Status and Outlook) 2024-2030

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).

The global Malignant Mesothelioma market size is projected to grow from US$ 425.5 million in 2023 to US$ 649.3 million in 2030; it is expected to grow at a CAGR of 6.2% from 2024 to 2030.

LPI (LP Information)' newest research report, the “Malignant Mesothelioma Industry Forecast” looks at past sales and reviews total world Malignant Mesothelioma sales in 2023, providing a comprehensive analysis by region and market sector of projected Malignant Mesothelioma sales for 2024 through 2030. With Malignant Mesothelioma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Malignant Mesothelioma industry.

This Insight Report provides a comprehensive analysis of the global Malignant Mesothelioma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Malignant Mesothelioma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Malignant Mesothelioma market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Malignant Mesothelioma and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Malignant Mesothelioma.

Our research indicates that the hospital pharmacies distribution channel segment is expected to witness a significant rise in revenue share over the forecast period, owing to the increasing direct procurement of mesothelioma drugs by governments to ensure availability in hospital pharmacies and oncology centers.

This report presents a comprehensive overview, market shares, and growth opportunities of Malignant Mesothelioma market by product type, application, key players and key regions and countries.

Segmentation by type
Oral
Parenteral

Segmentation by application
Hospital Pharmacies
Retail Pharmacies
Oncology Centers
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Bristol-Myers Squibb
Roche
Merck
Novartis
Pfizer
Sanofi
Eli Lilly
Teva Pharmaceuticals
Boehringer Ingelheim GmbH
Mylan
Fresenius Kabi
Sun Pharmaceuticals
Corden Pharma
Concordia International
Kyowa Hakko Kirin
Polaris Pharmaceuticals
MolMed
Ono Pharmaceutical
Nichi-Iko Pharmaceutical

Please note: The report will take approximately 2 business days to prepare and deliver.